Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients  Stephanie Farnia,

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,  
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Vaccination of Children following Allogeneic Stem Cell Transplantation
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Allogeneic Stem Cell Transplantation in Myelofibrosis
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Access to Hematopoietic Cell Transplantation in the United States
Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Caroline F. Morrison, Donna M
Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children  Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients  Elizabeth T. Loggers, Thomas.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities  Jaime M. Preussler, Lih-Wen Mau,
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Estimating Propensity Scores for the Receipt of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Outcomes Research Using Claims Data: A Machine.
B Cells and Transplantation: An Educational Resource
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients  James L. Gajewski, Mark.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Rammurti.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pauline Damien, David S. Allan 
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation 
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match  Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,
Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives  Minakshi Raj, Sung Won Choi,
Blood and Marrow Transplant Handbook
A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome  Peggy A. Wu,
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Hematopoietic Stem Cell Transplantation in Australia and New Zealand,  
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic.
Presentation transcript:

Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients  Stephanie Farnia, Alex Ganetsky, Alicia Silver, Theresa Hwee, Jaime Preussler, Joan Griffin, Nandita Khera  Biology of Blood and Marrow Transplantation  Volume 23, Issue 8, Pages 1387-1392 (August 2017) DOI: 10.1016/j.bbmt.2017.04.010 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 MA HMO preferred pharmacy. Biology of Blood and Marrow Transplantation 2017 23, 1387-1392DOI: (10.1016/j.bbmt.2017.04.010) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 MA HMO mail-order pharmacy. Biology of Blood and Marrow Transplantation 2017 23, 1387-1392DOI: (10.1016/j.bbmt.2017.04.010) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 MA PPO preferred pharmacy. Biology of Blood and Marrow Transplantation 2017 23, 1387-1392DOI: (10.1016/j.bbmt.2017.04.010) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 MA PPO mail-order pharmacy. Biology of Blood and Marrow Transplantation 2017 23, 1387-1392DOI: (10.1016/j.bbmt.2017.04.010) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.